These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 16040383)

  • 21. Vascular endothelial growth factor blockade reduces intratumoral regulatory T cells and enhances the efficacy of a GM-CSF-secreting cancer immunotherapy.
    Li B; Lalani AS; Harding TC; Luan B; Koprivnikar K; Huan Tu G; Prell R; VanRoey MJ; Simmons AD; Jooss K
    Clin Cancer Res; 2006 Nov; 12(22):6808-16. PubMed ID: 17121902
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synergy between dendritic cells and GM-CSF-secreting tumor cells for the treatment of a murine renal cell carcinoma.
    Driessens G; Hoffmann P; Pouwels M; Zlotta A; Schulman C; Velu T; Bruyns CA
    J Immunother; 2009; 32(2):140-4. PubMed ID: 19238012
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhancement of the anti-tumor efficacy of a GM-CSF-secreting tumor cell immunotherapy in preclinical models by cytosine arabinoside.
    Lin JM; Li B; Rimmer E; VanRoey M; Jooss K
    Exp Hematol; 2008 Mar; 36(3):319-28. PubMed ID: 18279719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor promote malignant growth of cells from head and neck squamous cell carcinomas in vivo.
    Gutschalk CM; Herold-Mende CC; Fusenig NE; Mueller MM
    Cancer Res; 2006 Aug; 66(16):8026-36. PubMed ID: 16912178
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Preclinical evaluation of DISC-GMCSF for the treatment of breast carcinoma.
    Loudon PT; McLean CS; Martin G; Curry J; Leigh Shaw M; Hoogstraten C; Verdegaal E; Osanto S
    J Gene Med; 2003 May; 5(5):407-16. PubMed ID: 12731089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kaempferol and quercetin stimulate granulocyte-macrophage colony-stimulating factor secretion in human prostate cancer cells.
    Bandyopadhyay S; Romero JR; Chattopadhyay N
    Mol Cell Endocrinol; 2008 Jun; 287(1-2):57-64. PubMed ID: 18346843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Experimental production of clinical-grade dendritic cell vaccine for acute myeloid leukemia.
    Tan YF; Sim GC; Habsah A; Leong CF; Cheong SK
    Malays J Pathol; 2008 Dec; 30(2):73-9. PubMed ID: 19291915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. TARC and RANTES enhance antitumor immunity induced by the GM-CSF-transduced tumor vaccine in a mouse tumor model.
    Inoue H; Iga M; Xin M; Asahi S; Nakamura T; Kurita R; Nakayama M; Nakazaki Y; Takayama K; Nakanishi Y; Tani K
    Cancer Immunol Immunother; 2008 Sep; 57(9):1399-411. PubMed ID: 18286286
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Anti-programmed death-1 synergizes with granulocyte macrophage colony-stimulating factor--secreting tumor cell immunotherapy providing therapeutic benefit to mice with established tumors.
    Li B; VanRoey M; Wang C; Chen TH; Korman A; Jooss K
    Clin Cancer Res; 2009 Mar; 15(5):1623-34. PubMed ID: 19208793
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor vaccine therapy against recrudescent tumor using dendritic cells simultaneously transfected with tumor RNA and granulocyte macrophage colony-stimulating factor RNA.
    Naka T; Iwahashi M; Nakamura M; Ojima T; Nakamori M; Ueda K; Katsuda M; Miyazawa M; Ishida K; Yamaue H
    Cancer Sci; 2008 Feb; 99(2):407-13. PubMed ID: 18271939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cell encapsulation technology as a novel strategy for human anti-tumor immunotherapy.
    Schwenter F; Zarei S; Luy P; Padrun V; Bouche N; Lee JS; Mulligan RC; Morel P; Mach N
    Cancer Gene Ther; 2011 Aug; 18(8):553-62. PubMed ID: 21566667
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Enhancing the clinical activity of granulocyte-macrophage colony-stimulating factor-secreting tumor cell vaccines.
    Jinushi M; Hodi FS; Dranoff G
    Immunol Rev; 2008 Apr; 222():287-98. PubMed ID: 18364009
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Established B16 tumors are rejected following treatment with GM-CSF-secreting tumor cell immunotherapy in combination with anti-4-1BB mAb.
    Li B; Lin J; Vanroey M; Jure-Kunkel M; Jooss K
    Clin Immunol; 2007 Oct; 125(1):76-87. PubMed ID: 17706463
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acute myeloid leukemia or myelodysplastic syndrome following use of granulocyte colony-stimulating factors during breast cancer adjuvant chemotherapy.
    Hershman D; Neugut AI; Jacobson JS; Wang J; Tsai WY; McBride R; Bennett CL; Grann VR
    J Natl Cancer Inst; 2007 Feb; 99(3):196-205. PubMed ID: 17284714
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine.
    Holmes JP; Benavides LC; Gates JD; Carmichael MG; Hueman MT; Mittendorf EA; Murray JL; Amin A; Craig D; von Hofe E; Ponniah S; Peoples GE
    J Clin Oncol; 2008 Jul; 26(20):3426-33. PubMed ID: 18612158
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recombinant GM-CSF plus autologous tumor cells as a vaccine for patients with mesothelioma.
    Powell A; Creaney J; Broomfield S; Van Bruggen I; Robinson B
    Lung Cancer; 2006 May; 52(2):189-97. PubMed ID: 16563560
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase 1/2 trial of autologous tumor mixed with an allogeneic GVAX vaccine in advanced-stage non-small-cell lung cancer.
    Nemunaitis J; Jahan T; Ross H; Sterman D; Richards D; Fox B; Jablons D; Aimi J; Lin A; Hege K
    Cancer Gene Ther; 2006 Jun; 13(6):555-62. PubMed ID: 16410826
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of polyvalent allogeneic vaccines.
    Van Epps D
    Dev Biol (Basel); 2004; 116():79-90; discussion 133-43. PubMed ID: 15603185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Vaccines in cancer: GVAX, a GM-CSF gene vaccine.
    Nemunaitis J
    Expert Rev Vaccines; 2005 Jun; 4(3):259-74. PubMed ID: 16026242
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vaccination of melanoma patients using dendritic cells loaded with an allogeneic tumor cell lysate.
    Salcedo M; Bercovici N; Taylor R; Vereecken P; Massicard S; Duriau D; Vernel-Pauillac F; Boyer A; Baron-Bodo V; Mallard E; Bartholeyns J; Goxe B; Latour N; Leroy S; Prigent D; Martiat P; Sales F; Laporte M; Bruyns C; Romet-Lemonne JL; Abastado JP; Lehmann F; Velu T
    Cancer Immunol Immunother; 2006 Jul; 55(7):819-29. PubMed ID: 16187085
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.